COVID pts Hypercoagulable - Heparin dosing adjustments

PLEASE NOTE:   Posts made to this forum should not be considered as the expressed opinions of, nor should be considered endorsed by, the Medication Safety Officer’s Society (MSOS) or the Institute for Safe Medication Practices (ISMP). 

Make sure your email is up-to-date
In order to continue to receive updates from MSOS, as well as forum posts and other valuable information as a member of MSOS, please be sure to update your email address with us, whenever it changes. If you need assistance doing so, please send an email to jrufo@ismp.org. 

6 posts / 0 new
Log in or register to post comments
Last post
Thu, 04/02/2020 - 13:13
#1
Jameika M. Stuckey
Jameika M. Stuckey's picture
Offline
Last seen: 1 year 4 months ago
Joined: 02/13/2018 - 15:27
COVID pts Hypercoagulable - Heparin dosing adjustments

Hey all,

I know that things are changing by the minute in this environment. However, we are seeing a consistent trend of COVID-19 patients being hypercoagulable. We are working to quickly develop an additional portion of our heparin dosing protocol specifically for these patients. We are watching list-servs all over the place. We plan to increase the therapeutic ranges but are wanting to do it as safely a possible. What, if anything yet, are you guys doing at your respective institutions. I am especially interested in hearing from academic medical centers, but would love to hear from any and everyone.

Thanks in advance!

Jameika

Jameika M. Stuckey, PharmD, BCACP
PCAP Clinical Supervisor
Medication Safety Manager
PGY-1 Pharmacy Residency Co-Coordinator
Department of Pharmacy Services
University of Mississippi Medical Center
2500 North State Street
Jackson, MS 39216
T: (601) 815-3856 | F: (601) 984-2063
Email: jmstuckey@umc.edu

Top